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Is No Simple Matter
Lessons to Be Learned From Our Anatomy?*Felix Mahfoud, MD,y Elazer R. Edelman, MD, PHD,zx Michael Böhm, MDyH ypertension remains the most prevalentcardiovascular risk factor around the globe,and a large body of previously published
literature examined the impact of the sympathetic
nervous system on hypertension and vascular disease
(1). In humans, sympathetic nerve activity is in-
creased in almost all forms of hypertension and
its comorbidities when measured according to mus-
cle sympathetic nerve activity (2,3). Catheter-based
approaches to renal sympathetic denervation may
provide new treatment options for patients with
resistant hypertension and bring the sympathetic
nervous system back to center stage in cardiovascular
medicine (1).
The relevance and variation in distribution and
density of the renal sympathetic nervous system
in humans have not been investigated sufﬁciently
in the past, and treatment recommendations for
catheter-based renal denervation have therefore
been based on what now appears anecdotal or inap-
propriate extrapolation from other organ systems.SEE PAGE 635In this issue of the Journal, Sakakura et al. (4) thor-
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be beneﬁcial. The authors investigated the anatomic
distribution of renal sympathetic nerves in human
autopsy subjects (40 renal arteries from 20 patients)
and provided the following insight:
1. The maximum average number of nerves was
observed in the proximal and middle segments of
the renal artery and the least number in the distal
segments.
2. The mean distance from the lumen to nerve was
highest in the proximal and lowest in the distal
segments.
3. The circumferential distribution was greatest in
the ventral region and least in the dorsal regions.
4. The density of efferent ﬁbers was far higher than
afferent ﬁbers.
5. Accessory renal arteries are surrounded by sym-
pathetic nerves.
6. No differences in nerve anatomy in hypertensive
subjects compared with nonhypertensive subjects
were observed.
These data suggest that asymmetric targeting is
required to achieve denervation of renal afferent and
efferent nerves and that the variability in target anat-
omy plays a causative role in achieving effective
treatment. The ﬂipside of the argument also prevails as
to whether the present ﬁndings can or should impact
our clinical practice in performing the procedure. The
ablation depth of the currently available radio-
frequency renal denervation systems varies between 2
and 4mm, which in fact limits the accessibility of renal
nerves by radiofrequency energy delivery in some re-
gions of the renal artery. The density of renal nerves is
higher in proximal segments compared with distal
segments of the renal arteries, although with
increasing distance from the aorta, radial nerve and
ganglia distributions are localized closer to the
lumen (Figs. 1A to 1C). The cumulative percentile of
FIGURE 1 Distribution and Density of Renal Sympathetic Nerves
Distribution of nerves stratiﬁed according to total number (each green dot represents 10 nerves), relative number as percent per segment, and distance from the lumen in
relative (A) proximal, (B) middle, and (C) distal location. Figure prepared using raw data from Sakakura et al. (4), and from raw data provided by M. Joner, of CVPath Inc.
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645nerves at 3 mm is w50% in the proximal and mid-
dle segment and 75% in the distal segment. There-
fore, one could argue that energy delivery should
focus on the proximal part of the renal arteries,
where the density of the nerves (efferent and
afferent) is highest (Fig. 1A). However, the distance
from the arterial lumen to nerves is shorter in the
distal segment, which might translate into more
effective and complete ablations, given the treat-
ment pattern of the available radiofrequency de-
vices (Fig. 1C). The situation is even more complex
because there also seem to be differences in the
circumferential location of the nerves, with the
greatest number of nerves in the ventral region
(11.0  3.5 per section) compared with the dorsal
region (6.2  3.0 per section; p < 0.001).
Due to the high variability in renal nerve density,
the efﬁcacy of intravascular renal denervation within
a given renal artery segment, particularly by single
electrodes, seems to be dependent on the circumfer-
ential location and depth from the luminal surface of
sympathetic nerves and ganglia. Indeed, the available
evidence suggests that renal denervation reduces
renal sympathetic activity (5) as well as reduces ofﬁce
and ambulatory blood pressure in open-label regis-
tries and randomized controlled trials (6–11) in certain,
but not all, patients. It was well understood that the
small, single-center studies which suggested the ef-
fects of renal denervation in resistant hypertension
required validation in the arena of full-ﬂedged clinical
trials and real-world studies (12,13). Thus, the ﬁrst
blinded, sham-controlled Symplicity HTN-3 (Renal
Denervation in Patients With Uncontrolled Hyper-
tension) study, which investigated renal denervationcompared with invasive sham treatment in patients
with severe therapy-resistant hypertension, met its
primary safety endpoint but failed to reach its primary
efﬁcacy endpoint (14). The difference in ofﬁce and
ambulatory systolic blood pressure between the
renal denervation group and the sham group did not
reach statistical signiﬁcance. Indeed, blood pressure
response after renal denervation varies, and in the
Symplicity HTN-1 trial (Percutaneous renal denerva-
tion in patients with treatment-resistant hyperten-
sion), response to renal denervation was arbitrarily
deﬁned as a systolic blood pressure reduction of >10
mm Hg 6 months after treatment. This threshold was
thought to represent a clinical meaningful reduction
of blood pressure that would translate into a reduction
in cardiovascular risk (15). The Symplicity HTN-3 trial
failed, but using this deﬁnition, 58% of the patients
treated with renal denervation and 48% of patients
in the sham group (p ¼ 0.04) met the 10–mm Hg
blood pressure reduction at the 6-month follow-up.
In addition, other procedural outliers may have
been potential reasons for no or minor blood pressure
changes after renal denervation (15). In Symplicity
HTN-3, a total of 535 patients were recruited in 88
centers, but 111 operators performed 364 renal dener-
vation procedures (14). On average, operators per-
formed w3 procedures, but a reasonable number of
investigators performed even fewer and many only 1.
The procedures were performed by using the
ﬁrst-generation technology, a single electrode mono-
polar catheter system (Symplicity Flex, Medtronic,
Inc., Minneapolis, Minnesota) that deployed radio-
frequency energy to the vessel wall. There were
no means of assessing proper wall contact or effective
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646destruction of renal sympathetic nerves intrapro-
cedurally (16). Those who use radiofrequency ablation
of arrhythmias are aware that radiofrequency lesion
formation depends on good electrode–tissue contact,
power delivery, electrode–tissue interface tempera-
ture, target tissue impedance, and the size of the
catheter’s active electrode (17). This is important
because speciﬁc catheter reﬁnements and scientiﬁ-
cally sound treatment recommendations might help to
beneﬁcially inﬂuence treatment success. However,
one of the (anecdotal) procedural recommendations
using the Symplicity Flex catheter was to start the
denervation procedure distally inferior and, by pulling
and rotating the catheter tip, to perform at least 4 focal
treatments with an inferior, anterior, superior, and
posterior orientation of the catheter tip with a distance
of $5 mm between each location (18). Are these treat-
ment recommendations supported by biology? Can
treatment success be increased by concentrating
our ablation efforts on a speciﬁc region? How many
nerves need to be affected to signiﬁcantly decrease
noradrenaline kidney tissue content in animals and,
even more importantly, sympathetic nerve activity
and thereby blood pressure in humans: 10%, 50%,
or 100%?
Certainly, additional preclinical and clinical studies
are required to understand whether 1 size ﬁts all
or whether we will have to customize and reﬁnetreatments according to speciﬁc catheter features and,
potentially, patient characteristics in the future.
Despite the request to optimize treatment efﬁcacy,
new and revised devices have to show favorable safety
proﬁles because an intensiﬁed treatment algorithm
could potentially induce or promote renal artery ste-
nosis. New renal denervation catheter developments
and scientiﬁcally sound treatment recommendations
might help to further increase treatment success. The
results of Symplicity HTN-3 have provided valuable
momentum. The renal denervation procedure may be
technically easy; however, it is becomingmore obvious
that the importance of the complex underlying
anatomy and physiology as well as the biophysics of
radiofrequency lesion formation have been widely
underestimated. The ﬁndings presented in this issue
of the Journal (4) provide interesting information but
above all should stimulate investigators and device
manufactures to perform rigorous preclinical and
clinical studies to resolve essential questions and to
allow the ﬁeld to determine how, when, and why
effects can be anticipated.
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